Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Novellus
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394
Details : Under the terms of the agreement, Plexxikon grants Novellus rights to research, develop, manufacture and exclusively commercialize PLX8394 worldwide.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 03, 2020
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Novellus
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?